Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score

Table 4

Efficacy and prognosis based on the LIPI groups.

LIPI classification		Response rate		OS (months)		PFS (months)
		DCR (, %)	OR (95% CI)	Median	HR (95% CI)	Median	HR (95% CI)
The good	()	33 (86.8)	1 [reference]	20.2 (0.00-43.40)	1 [reference]	12.17 (4.29-20.05)	1 [reference]
The intermediate/poor	()	47 (65.3)	5.217 (1.439-18.917)	8.7 (6.59-10.81)	1.877 (1.076-3.275)	3.17 (1.77-4.56)	2.301 (1.395-3.796)
value		0.012		0.027		0.001

PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index.